Skip to main content

Table 1 Patient characteristics in the 1st line endocrine setting (n = 16)

From: Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors

Variable n (%), median (range)
Median age at AI initiation 55 years (39–72)
Performance status  
0 4 (25%)
1 10 (62.5%)
2 1 (6.25%)
3 1 (6.25%)
Menopausal status  
Premenopausal 2 (12.5%)
Postmenopausal 14 (87.5%)
Median body mass index 27.6 kg/m2 (20.3–52.7)
Number of co-morbidities  
0–1 13 (81%)
2–3 3 (19%)
4–5 0 (0%)
Stage at diagnosis  
Non metastatic 11 (69%)
Locally recurrent/ metastatic 5 (31%)
Sites of metastases at time of AI initiation  
Lung 12 (75%)
[Lung as only site of metastases] 10 (62.5%)
Pelvis 4 (25%)
Peritoneum 3 (19%)
Tumour volume at time of AI initiation  
Low 6 (37.5%)
High 10 (62.5%)
Number of metastases  
Oligometastatic 7 (44%)
Multiple 9 (56%)
  1. AI, aromatase inhibitor.